A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine

NCT04683224 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study was withdrawn due to redesign of the protocol.

Conditions

Covid-19
SARS-CoV-2
Coronavirus

Interventions

BIOLOGICAL: UB-612
OTHER: Placebo

Sponsor

Vaxxinity, Inc.

Collaborators

[object Object]